News
Press Release | September 10, 2022
ImCheck Presents Positive Safety and Efficacy Data from the Completed Phase 1 Dose Escalation Cohort of ICT01 plus Pembrolizumab in the EVICTION Trial at ESMO Congress 2022
Press Release | September 1, 2022
Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis
Press Release | July 26, 2022
Affini-T Therapeutics Appoints Pioneering T Cell Therapy and KRAS Developer Dirk Nagorsen, M.D., as Chief Medical Officer
Press Release | July 11, 2022
Pliant Therapeutics Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis
Press Release | July 5, 2022
Skyhawk Announces Collaboration Agreement with Sanofi for Oncology and Immunology Targets
Press Release | June 21, 2022
Carbon Biosciences Launches with $38 Million Series A Financing to Advance Novel Gene Therapy Platform and Pipeline
Press Release | June 13, 2022
ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody and Accelerate Development of Disruptive Immunotherapeutic Pipeline
Press Release | May 15, 2022
Zenas BioPharma Submits Investigational New Drug Application in China for ZB001 for the Treatment of Thyroid Eye Disease
Press Release | May 2, 2022
Gilead follows Big Pharma peers to Dragonfly’s pond in $300M deal for natural killer cell engagers
Press Release | April 20, 2022
Dragonfly Therapeutics Announces Multi-Target Expansion of its Research Collaboration with AbbVie to Develop Novel Therapeutic Candidates for Immune-Mediated Diseases
Press Release | April 8, 2022
ImCheck Provides Updated ICT01 and Pembrolizumab Combination Data from the Phase I/IIa EVICTION Trial at AACR Annual Meeting 2022
Press Release | April 8, 2022
Pyxis Oncology Announces Preclinical Data on Anti-Siglec-15 BSI-060T (PYX-106) Presented by Biosion, Inc. at the 2022 American Association for Cancer Research (AACR) Annual Meeting
News | March 22, 2022
Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations
Press Release | March 1, 2022
Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb
Press Release | February 28, 2022
Freenome Launches the Vallania Study for the Early Detection of Multiple Cancers
News | February 28, 2022
Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Fibromyalgia
1
2